CoChat

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Abstract

Background Checkpoint inhibitors are standard adjuvant treatment for stage IIB-IV resected melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 (V940), a novel mRNA-based individualised neoantigen therapy, combined with pembrolizumab, improved recurrence-free survival and distant metastasis-free survival versus pembrolizumab monotherapy in resected high-risk melanoma. Methods We did an open-label, randomised, phase 2b, adjuvant study of mRNA-4157 plus pembrolizumab versus pembrolizumab monotherapy in patients, enrolled from sites in the USA and Australia, with completely resected high-risk cutaneous melanoma. Patients with completely resected melanoma (stage IIIB-IV) were assigned 2:1 to receive open-label mRNA-4157 plus pembrolizumab or pembrolizumab monotherapy. mRNA-4157 was administered intramuscularly (maximum nine doses) and pembrolizumab intravenously (maximum 18 doses) in 3-week cycles. The primary endpoint was recurrence-free survival in the intention-to-treat population. This ongoing trial is registered at ClinicalTrials.gov, NCT03897881. Findings From July 18, 2019, to Sept 30, 2021, 157 patients were assigned to mRNA-4157 plus pembrolizumab combination therapy (n=107) or pembrolizumab monotherapy (n=50); median follow-up was 23 months and 24 months, respectively. Recurrence-free survival was longer with combination versus monotherapy (hazard ratio [HR] for recurrence or death, 0·561 [95% CI 0·309-1·017]; two-sided p=0·053), with lower r…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)02268-7

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Zhong, 2020, Bioinformatics algorithm of mRNA-4157 identifies neoantigens with pre-existing TIL reactivities in colorectal tumors, Cancer Res, 80

Cited by

See all 974

Metadata

Authors
Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., Faries, M., Tran, T. T., Cowey, C. L., Pecora, A., Shaheen, M., Segar, J., Medina, T., Atkinson, V., Gibney, G. T., Luke, J. J., Thomas, S., Buchbinder, E. I., Healy, J. A., Huang, M., Morrissey, M., Feldman, I., Sehgal, V., Robert-Tissot, C., Hou, P., Zhu, L., Brown, M., Aanur, P., Meehan, R. S., & Zaks, T.
Affiliations
  • NYU Langone’s Laura and Isaac Perlmutter Cancer Center (US)
  • Westmead Hospital (AU)
  • Edith Cowan University (AU)
  • St John of God Subiaco Hospital (AU)
  • Washington University in St. Louis (US)
  • Providence Portland Medical Center (US)
  • California Pacific Medical Center (US)
  • Sarah Cannon (US)
  • The University of Sydney (AU)
  • Harvard University (US)
  • Angeles Clinic and Research Institute (US)
  • Yale New Haven Hospital (US)
  • Hackensack University Medical Center (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • University of Arizona (US)
  • University of Colorado Cancer Center (US)
  • Princess Alexandra Hospital (AU)
  • Georgetown Lombardi Comprehensive Cancer Center (US)
  • UPMC Hillman Cancer Center (US)
  • Orlando Health (US)
  • Dana-Farber Cancer Institute (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Moderna Therapeutics (United States) (US)
Corresponding author
Weber, Jeffrey S
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-02
Volume
403
Issue
10427
Pages
632-644
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4391067309
Cited by
916
References
30
Citations by year
2026: 389 · 2025: 363 · 2024: 164
FWCI
156.85
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Moderna Therapeutics Inc
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
pembrolizumab, resected melanoma, adjuvant therapy, recurrence-free survival, distant metastasis-free survival, immune checkpoint inhibitors, combination therapy, immunotherapy
MeSH terms
Adjuvants, Immunologic, Antineoplastic Combined Chemotherapy Protocols, Humans, Melanoma, Skin Neoplasms, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. https://app.cochat.ai/papers/10.1016/s0140-6736(23)02268-7
The paper
Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., Faries, M., Tran, T. T., Cowey, C. L., Pecora, A., Shaheen, M., Segar, J., Medina, T., Atkinson, V., Gibney, G. T., . . . Zaks, T. (2024). Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. The Lancet. https://doi.org/10.1016/s0140-6736(23)02268-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.